JP2010065037A5 - - Google Patents

Info

Publication number
JP2010065037A5
JP2010065037A5 JP2009233816A JP2009233816A JP2010065037A5 JP 2010065037 A5 JP2010065037 A5 JP 2010065037A5 JP 2009233816 A JP2009233816 A JP 2009233816A JP 2009233816 A JP2009233816 A JP 2009233816A JP 2010065037 A5 JP2010065037 A5 JP 2010065037A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
apo
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009233816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010065037A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010065037A publication Critical patent/JP2010065037A/ja
Publication of JP2010065037A5 publication Critical patent/JP2010065037A5/ja
Pending legal-status Critical Current

Links

JP2009233816A 2002-06-24 2009-10-07 Apo−2リガンド/trail変異体とその使用法 Pending JP2010065037A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39105002P 2002-06-24 2002-06-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004516142A Division JP4574350B2 (ja) 2002-06-24 2003-06-23 Apo−2リガンド/trail変異体とその使用法

Publications (2)

Publication Number Publication Date
JP2010065037A JP2010065037A (ja) 2010-03-25
JP2010065037A5 true JP2010065037A5 (enExample) 2010-12-09

Family

ID=30000661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004516142A Expired - Lifetime JP4574350B2 (ja) 2002-06-24 2003-06-23 Apo−2リガンド/trail変異体とその使用法
JP2009233816A Pending JP2010065037A (ja) 2002-06-24 2009-10-07 Apo−2リガンド/trail変異体とその使用法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004516142A Expired - Lifetime JP4574350B2 (ja) 2002-06-24 2003-06-23 Apo−2リガンド/trail変異体とその使用法

Country Status (7)

Country Link
US (4) US20060141561A1 (enExample)
EP (2) EP2500032A1 (enExample)
JP (2) JP4574350B2 (enExample)
AU (2) AU2003247609A1 (enExample)
CA (1) CA2489348A1 (enExample)
IL (1) IL165777A0 (enExample)
WO (1) WO2004001009A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1501866A4 (en) * 2001-10-02 2006-02-08 Genentech Inc VARIANTS OF THE LIGAND APO-2 AND USES THEREOF
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
KR20060132006A (ko) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
JP2008513367A (ja) * 2004-09-08 2008-05-01 ジェネンテック・インコーポレーテッド デスレセプターリガンド及びcd20抗体の使用方法
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
KR100886783B1 (ko) * 2006-06-12 2009-03-04 성균관대학교산학협력단 N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
WO2008088582A2 (en) * 2006-08-04 2008-07-24 Mayo Foundation For Medical Education And Research Methods and materials related to trail isoforms
WO2009040811A2 (en) 2007-09-24 2009-04-02 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
US8633297B2 (en) * 2007-10-31 2014-01-21 Medimmune, Llc Protein scaffolds
WO2011079293A1 (en) * 2009-12-23 2011-06-30 Ambrx, Inc Tumor necrosis factor-related apoptosis inducing ligand polypeptides and their uses
WO2011130324A1 (en) 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
EP3753567A1 (en) 2011-10-11 2020-12-23 Viela Bio, Inc. Cd40l-specific tn3-derived scaffolds and methods of use thereof
JP6219923B2 (ja) 2012-03-28 2017-10-25 アムジェン インコーポレイテッド Dr5受容体アゴニストの組み合わせ
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
KR20150133576A (ko) * 2014-05-20 2015-11-30 삼성전자주식회사 화학적 개질된 표적화 단백질 및 그의 이용
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
WO2018183671A1 (en) 2017-03-29 2018-10-04 Tdw Group Protein conjugates
IT201900024622A1 (it) * 2019-12-18 2021-06-18 Univ Degli Studi G Dannunzio Chieti Pescara Pegilazione innovativa del killer tnf-apoptosis induced ligand (killer-trail)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
KR0154872B1 (ko) 1987-12-21 1998-10-15 로버트 에이. 아미테이지 발아하는 식물종자의 아크로박테리움 매개된 형질전환
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
WO1992003478A1 (en) 1990-08-17 1992-03-05 Genentech, Inc. Metal ion mediated receptor binding of polypeptide hormones
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
AU1757092A (en) 1991-03-28 1992-11-02 Genentech Inc. Stable growth hormone metal ion formulations
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
EP0679095A1 (en) 1992-11-25 1995-11-02 Amgen Boulder Inc. Modified insulin-like growth factors
AU6626794A (en) 1993-04-07 1994-10-24 Amgen Boulder Inc. Methods of using insulin-like growth factor binding proteins
JPH09504174A (ja) * 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ,インク. プロテアーゼネキシン1変異体を含むキメラ蛋白
DK1666591T3 (da) 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
DK0851925T3 (da) 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
PT1012274E (pt) 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
JP2001511162A (ja) 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして/又は除去された付着基を有するポリペプチド−ポリマー結合体
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
JP4330180B2 (ja) 1997-03-17 2009-09-16 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 死ドメイン含有レセプター5
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
AU7126498A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Tumor necrosis factor receptor related proteins tango-63d and tango-63e
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
CA2301202A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
AU8485098A (en) 1997-08-26 1999-03-16 Genentech Inc. Rtd receptor
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
JP2002508962A (ja) 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Apo−2リガンド
AU2338299A (en) 1998-01-26 1999-08-09 Genentech Inc. Antibodies to death receptor 4 (dr4) and uses thereof
ATE330972T1 (de) 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
US6318934B1 (en) * 1999-06-24 2001-11-20 Anchor Wall Systems, Inc. Segmental retaining wall system
CN101633692A (zh) * 1999-06-28 2010-01-27 杰南技术公司 利用二价金属离子制备Apo-2配体的方法
DE60136816D1 (de) 2000-07-27 2009-01-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
EP1501866A4 (en) * 2001-10-02 2006-02-08 Genentech Inc VARIANTS OF THE LIGAND APO-2 AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2010065037A5 (enExample)
JP2010227108A5 (enExample)
JP2011136981A5 (enExample)
JP2009268467A5 (enExample)
JP2011155981A5 (enExample)
JP2011177189A5 (enExample)
JP2013510581A5 (enExample)
JP2014501510A5 (enExample)
JP2010532978A5 (enExample)
JP2020022459A5 (enExample)
JP2012095652A5 (enExample)
JP2011134884A5 (enExample)
JP2012070736A5 (enExample)
JP2010501534A5 (enExample)
JP2010519252A5 (enExample)
JP2007510403A5 (enExample)
JP2007175057A5 (enExample)
JP2013539454A5 (enExample)
JP2009524695A5 (enExample)
JP2011087580A5 (enExample)
JP2013507132A5 (enExample)
JP2007508034A5 (enExample)
JP2014028813A5 (enExample)
JP2009542225A5 (enExample)
JP2009504138A5 (enExample)